Should I Buy CABA? CABA 2026 Analysis

Should You Buy Cabaletta Bio Inc (CABA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.510

1 Day change

7.73%

52 Week Range

3.670

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: there’s no Intellectia buy signal today, no fresh news catalyst, and momentum is weakening near a key pivot level.
Trend is generally constructive (bullish moving-average stack), but price is still below the pivot (2.763) and MACD is contracting, which often precedes chop/pullbacks.
Options positioning is very call-skewed (bullish sentiment), but without a near-term catalyst this can fail to translate into immediate upside.
Better risk/reward would appear after a clean reclaim/hold above ~~2.76 (pivot) or a bounce confirmation off ~2.32 support; at the current pre-market level (~~2.61) the setup is not compelling enough to call a “good buy now.”

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock today.

Technical Analysis

Current price (pre-market): ~2.61, below Pivot 2.763 → near-term trend needs confirmation; still in the lower half of the pivot range.
Moving averages: bullish stack (SMA_5 > SMA_20 > SMA_200) → broader trend bias is upward.
MACD: histogram slightly positive (0.00604) but positively contracting → bullish momentum is fading rather than accelerating.
RSI(6): 47.389 (neutral) → no oversold/overbought edge right now.
Key levels: Support S1 2.32 (then S2 2.046); Resistance R1 3.206 (then R2 3.48).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: extremely call-heavy positioning (OI put/call 0.08; volume put/call 0.09) → bullish/speculative tilt.
Activity: today’s options volume 1,289 with volume vs 30D avg at 45.16 (very elevated) → traders are actively positioning.
Volatility: very high (HV ~171%, IV30 ~146%); IV percentile ~56.8 → options are expensive but not at extremes; market is pricing large moves.
Interpretation: bullish skew is supportive, but it can also indicate crowded upside bets—without catalysts, price can stall despite call demand.

Technical Summary

Sell

Buy

Positive Catalysts

- Technical backdrop is generally bullish via moving-average alignment (trend bias up).
- Options market positioning is strongly risk-on (heavy call skew) and activity is elevated, which can help fuel short squeezes/rallies if any catalyst appears.
- Pattern-based projection (similar candlesticks): +2.79% next week and +2.92% next month probabilities outweighing the modeled next-day dip.

Neutral/Negative Catalysts

- No news in the last week → lack of immediate event-driven catalyst for an impatient timeframe.
- MACD momentum is contracting while price sits below the 2.763 pivot → higher chance of chop or a dip toward support before a sustainable push.
- Biotech profile with no revenue (latest quarter) keeps the stock highly sentiment/financing dependent.
- Hedge funds and insiders: neutral (no notable accumulation signal recently).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 0 (0.00% YoY) → still pre-commercial.
Net income: -44.866M, improved 46.48% YoY → loss narrowed year-over-year.
EPS: -0.44, down 29.03% YoY → per-share profitability worsened despite net loss improvement (likely share count/other items impacting EPS).
Overall: financials show reduced net loss YoY, but the company remains loss-making with no revenue base.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

2026-01-08: Morgan Stanley maintained Overweight but cut price target to $14 from $22.
Trend read: rating remains positive, but the target cut signals reduced conviction in upside magnitude or a reassessment of timeline/risks.
Wall Street pros: still seen as a potential outperformer within small/mid-cap biotech.
Wall Street cons: meaningful target reduction suggests higher perceived risk, longer path to value realization, or weaker near-term setup.

9 Analyst Rating

Wall Street analysts forecast CABA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CABA is 15.86 USD with a low forecast of 4 USD and a high forecast of 30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

1 Hold

0 Sell

Strong Buy

Current: 2.330

Low

Averages

15.86

High

Current: 2.330

Low

Averages

15.86

High

Morgan Stanley

Overweight

downgrade

$22 -> $14

AI Analysis

2026-01-08

Reason

Morgan Stanley

Price Target

$22 -> $14

AI Analysis

2026-01-08

downgrade

Overweight

Reason

Morgan Stanley lowered the firm's price target on Cabaletta Bio to $14 from $22 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

Cantor Fitzgerald

Overweight

upgrade

$15 -> $30

2025-10-31

Reason

Cantor Fitzgerald

Price Target

$15 -> $30

2025-10-31

upgrade

Overweight

Reason

Cantor Fitzgerald raised the firm's price target on Cabaletta Bio to $30 from $15 and keeps an Overweight rating on the shares. Auto-CAR-T is showing unprecedented and transformational efficacy in scleroderma, and investors aren't appreciating how substantial this unmet need is, the analyst says in a research note, adding that bispecifics are also starting to look "good."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CABA

Unlock Now

CABA Should I Buy

CABA Should I Buy

Should You Buy Cabaletta Bio Inc (CABA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch